Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Wisconsin for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Wisconsin only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Wisconsin (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Paula Gill (NPI 1750363909)

Field	Value
Entity Type	Individual
Organization	Paula Gill
Address	800 West Ave S
City	La Crosse
State	WI
ZIP	54601
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	November 15, 2005

Payer Source	Total Paid
Medicare	$997.3K
Medicaid	$0

Key Findings

This provider is an oncology-focused practice: taxonomy lists Hematology & Oncology Physician and the top billed items are high-cost oncology infusions. The three highest-revenue Medicare codes are J9271 ($426.4K, 43.2% of Medicare revenue), J9144 ($212.1K, 21.5%), and J9299 ($153.6K, 15.5%), and those drug codes — all checkpoint inhibitors or monoclonal antibody therapies — dominate the clinical and revenue mix. The precomputed summary notes the top 3 Medicare codes account for 80.2% of this provider's total Medicare revenue, indicating the operation is heavily drug/infusion–centric rather than driven by office E/M visits or ancillary services.

Revenue concentration is high and concentrated in a few biologic agents: J9271 alone represents $426.4K (43.2%) of Medicare revenue while the top three codes together make up 80.2% of Medicare revenue. That concentration signals material exposure to utilization or pricing changes for those specific agents and suggests the practice’s profitability and throughput are tightly coupled to administration of pembrolizumab, daratumumab, and nivolumab.

Payer mix is effectively single‑payer Medicare: lifetime Medicare revenue is $997.3K and there is no Medicaid billing on file. Analysts should treat this provider as dependent on Medicare volume and payment policy, with little or no Medicaid exposure to diversify state-level payer risk.

Competitive standing on the top drugs is modest rather than dominant: J9271 ranks #1128 of 1841 providers nationally (38th percentile) and is flagged as "typical, unremarkable volume," J9144 ranks #459 of 615 (25th percentile) as "typical, unremarkable volume," and J9299 ranks #451 of 505 (11th percentile) also described as "typical, unremarkable volume." These ranks indicate a meaningful presence in administering these agents but not a leading national footprint for any of them.

Operating model includes outpatient infusion capabilities beyond drug billing: chemotherapy administration and infusion-related codes appear throughout the top list (96413, G0498, 96375, 96417, 96415), with 96413 contributing $26.6K (2.7% of Medicare revenue) and G0498 contributing $6.8K (0.7%). The presence of G0498 (office initiation with portable pump and follow-up) and multiple add-on infusion codes supports a clinic-based infusion service that occasionally coordinates extended or community-based infusions.

Clinical visit (E/M) billing is secondary to infusion drugs: highest E/M codes 99215 ($16.9K, 1.7%) and 99214 ($7.1K, 0.7%) appear well down the revenue list, indicating direct drug administration generates the bulk of billed dollars while evaluation-and-management services are a smaller revenue component. This mix is consistent with an infusion-centric oncology practice where drug reimbursements substantially outstrip cognitive visit revenue.

National percentile distribution shows most items are described as "typical, unremarkable volume," but several drug and biosimilar codes sit at low percentiles, indicating a small national footprint for those specific agents. Examples include J9264 (rank #112 of 118, 5th percentile, "typical, unremarkable volume"), Q5118 (rank #139 of 161, 14th percentile), and J2506 (rank #580 of 586, 1th percentile), which suggests selective or limited use of certain agents relative to peers.

Provider tenure is long-standing: NPI was enumerated 2005-11-15 (~21 years ago), indicating sustained participation in Medicare billing over two decades. For analysts evaluating network stability or contracting, that tenure supports continuity of care and experience in oncology infusion management.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,400	$40	$426.4K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,580	$40	$212.1K
J9299	Injection, nivolumab, 1 mg	6,400	$20	$153.6K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	1,530	$20	$35.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	250	$110	$26.6K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	1,020	$20	$23.5K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	2,580	$10	$23.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	140	$120	$16.9K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	80	$140	$10.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	140	$70	$10.2K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Wisconsin Distribution

Paula Gill — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Wisconsin

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9144	4	10	7,020	$40	$393.8K
J9271	3	10	8,000	$40	$382.7K
J9299	1	10	6,400	$20	$151.9K
Q5119	2	10	1,530	$20	$38.4K
J9264	1	10	2,580	$10	$24.1K
Q5118	1	10	1,020	$20	$23.5K
J3490	3	10	30	$260	$22.4K
J9217	32	30	130	$130	$20.9K
96413	10	80	110	$90	$12.7K
J2506	1	10	140	$70	$10.2K

Showing 1–10 of 45

Related Providers

Other providers that share a Tax Identification Number (TIN) with Paula Gill, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mayo Clinic Health System-southeast Minnesota Region	MN	General Acute Care Hospital	$0	$37.5M
Mayo Clinic	MN	Clinical Medical Laboratory	$12.2M	$15.2M
Mayo Clinic Health System-southeast Minnesota Region	MN	Multi-Specialty Clinic/Center	$0	$21.8M
Mayo Clinic Health System-southeast Minnesota Region	MN	Multi-Specialty Clinic/Center	$0	$13.7M
Mayo Clinic Health System-southwest Wisconsin Region, Inc.	WI	General Acute Care Hospital	$0	$13.4M
Mayo Clinic Health System-southeast Minnesota Region	MN	Substance Abuse Rehabilitation Facility	$0	$12.6M
Mayo Clinic Health System-southwest Wisconsin Region, Inc.	WI	Multi-Specialty Clinic/Center	$0	$8.8M
Mayo Clinic Health System-southwest Wisconsin Region, Inc.	WI	Critical Access Hospital	$0	$8.4M
Mayo Clinic Health System-southeast Minnesota Region	MN	General Acute Care Hospital	$0	$6.6M
Mayo Clinic Health System-southeast Minnesota Region	MN	Multi-Specialty Clinic/Center	$0	$4.4M

Nearby Providers

Other providers in the same ZIP code as Paula Gill, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
County Of La Crosse	WI	Community/Behavioral Health Agency	$0	$85M
Gundersen Lutheran Medical Center Inc	WI	General Acute Care Hospital	$0	$74.3M
Gundersen Clinic Ltd	WI	Clinic/Center	$0	$10.1M
Riverfront Activities Center Inc	WI	Developmentally Disabled Services Day Training Agency	$0	$7.2M
La Crosse County Human Services	WI	Community/Behavioral Health Agency	$0	$3.3M
School District Of La Crosse	WI	Local Education Agency (LEA)	$0	$2.8M
Gundersen Lutheran Medical Center, Inc.	WI	Air Ambulance	$0	$2M
Chileda Institute, Inc	WI	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$1.9M
Driftless Recovery Services, Inc.	WI	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$1.4M
Cindy Calderon	WI	Ophthalmology Physician	$897.7K	$4.1K

Paula Gill — Billing Profile & Reimbursement Data

Sign up for Paula Gill — Billing Profile & Reimbursement Data policy alerts

Paula Gill — Billing Profile & Reimbursement Data

Sign up for Paula Gill — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References